Three digitally enabled therapies can be used as treatment options for
adults with depression while further evidence is generated on their
clinical and cost effectiveness. The therapies should be used with
support from a trained practitioner or therapist in NHS Talking Therapies
for anxiety and depressio...
People with BRCA mutation-positive HER2‑negative high-risk early breast cancer usually have chemotherapy followed by surgery (neoadjuvant chemotherapy), or surgery followed by chemotherapy (adjuvant chemotherapy).
Clinical trial evidence shows that, compared with placebo, olaparib after neoadjuvant or...
This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...
Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.
Guidance development process
Early value assessment (EVA) guidance rapidly provides recommendations on promising health technologies that have the potential to address national...
Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments....
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults....
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults....
NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission....
People with relapsed or refractory diffuse large B-cell lymphoma who cannot have an
autologous stem cell transplant usually have polatuzumab vedotin plus rituximab and
bendamustine.
The clinical evidence is from a small study that did not directly compare tafasitamab plus
lenalidomide with any other trea...
